Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Moponetug · BMS-986446, PRX-005

Monoclonal antibody · developed by BRISTOL MYERS SQUIBB

Phase 1 Most advanced trial

BMY Developer

1 Registered trials

What is Moponetug?

Moponetug is an investigational antibody studied in Alzheimer's Disease, Healthy Participants.

At a glance

Also known as: BMS-986446, PRX-005
Drug type: Monoclonal antibody
Therapy area: Neurology
Developer: BRISTOL MYERS SQUIBB (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: H85U6L98FB

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07780383	Phase 1	Alzheimer's Disease	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's DiseaseHealthy Participants

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

ClinicalTrials.gov NCT07780383

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Moponetug

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z